EXACT Sciences Corporation (EXAS) Obtains Exclusive License to OncoMethylome Sciences S.A. DNA Methylation Biomarkers  
7/27/2010 8:25:35 AM

MADISON, Wis. & LIEGE, Belgium--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) and OncoMethylome Sciences S.A. (Brussels: ONCOB) today announced that they have entered into a license agreement under which Exact Sciences has obtained exclusive, worldwide rights to up to two OncoMethylome Sciences’ DNA methylation biomarkers for use in stool-based detection of colorectal cancer. Exact Sciences has also gained non-exclusive access to part of OncoMethylome’s platform technology. In return, OncoMethylome will receive milestone payments and royalties on net sales.